Understanding the state of pharmacogenomic testing for thiopurine methyltransferase within a large health system.
Pharmacogenomics
; 21(6): 411-418, 2020 04.
Article
in En
| MEDLINE
| ID: mdl-32308127
ABSTRACT
Aim:
To investigate the current state of TPMT testing at a single-academic medical center.Methods:
Single-center, retrospective chart review for patients newly prescribed a thiopurine. Data collection and evaluation included the prevalence and timing of TPMT testing, correct dosage adjustment if applicable, and incidence of myelosuppression.Results:
121 patients (71%) received TPMT testing. Out of the tested patients, 110 (90.9%) were designated as wild-type with normal metabolism. Dosing modification was appropriate in applicable patients. In unadjusted analysis, there was a lower incidence of myelosuppression among patients who were tested versus those who were not (16.5 vs 36.7%).Conclusion:
Based on the study results, TPMT testing opportunities exist for nearly 30% of patients. Testing may reduce the incidence of myelosuppression.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Delivery of Health Care
/
Pharmacogenomic Testing
/
Methyltransferases
Type of study:
Observational_studies
/
Risk_factors_studies
Aspects:
Determinantes_sociais_saude
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Country/Region as subject:
America do norte
Language:
En
Journal:
Pharmacogenomics
Journal subject:
FARMACOLOGIA
/
GENETICA MEDICA
Year:
2020
Document type:
Article
Affiliation country: